Yazar "Askin, Rustem" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Low-Dose Imipramine for Treatment of Panic Disorder During Pregnancy A Retrospective Chart Review
    (Lippincott Williams & Wilkins, 2014) Uguz, Faruk; Sahingoz, Mine; Gungor, Buket; Askin, Rustem
    Although imipramine is one of the antidepressants that could be effective in the treatment of panic disorder, data on its usage for this diagnosis in the pregnancy period are limited. This report presents the results of 16 pregnant women with panic disorder without comorbid diagnosis who underwent low-dose imipramine (10-40 mg/d) treatment. According to the Clinical Global Impression-Improvement Scale, 12 (75%) of 16 women responded to the treatment. The results suggest that low-dose imipramine may be useful for the treatment of panic disorder during pregnancy.
  • Küçük Resim Yok
    Öğe
    The prevalence of depression and anxiety disorders in patients with euthyroid Hashimoto's thyroiditis: a comparative study
    (Elsevier Science Inc, 2014) Ayhan, Medine Giynas; Uguz, Faruk; Askin, Rustem; Gonen, Mehmet Sait
    Objective: The aim of this study was to examine the current prevalence of major depression and anxiety disorders in patients with euthyroid Hashimoto's thyroiditis (HT) and euthyroid goiter. Method: The study sample was formed by consecutive 51 and 45 patients who were admitted to the endocrinology outpatient clinic and diagnosed with euthyroid HT and endemic/nonendemic goiter, respectively, and 68 healthy controls. Current diagnoses of psychiatric disorders were determined using the Structured Clinical Interview for DSM-IV. Beck Depression Inventory and Beck Anxiety Inventory were applied to the participants. Results: There was a statistically significant difference among the three groups in terms of major depression (P=.001), any mood or anxiety disorder (P=.000), any depressive disorder (P=.020), any anxiety disorder (P=.016) and obsessive-compulsive disorder (OCD) (P=.013). In the HT group, the prevalence of depression (P=.000), OCD (P=.005) and panic disorder (P=.041) was significantly higher than that in the control group. In the goiter group, depression (P=.006), any depressive disorder (P=.03), and any mood or anxiety disorder (P=.000) were significantly common in comparison to the control group. No significant difference was found between the HT and goiter groups. Conclusions: Euthyroid HT and euthyroid goiter increase predisposition to major depression and anxiety disorders, and thyroid autoimmunity and other thyroid pathologies should be investigated in euthyroid patients with chronic and treatment-resistant complaints. (C) 2014 Elsevier Inc. All rights reserved.
  • Küçük Resim Yok
    Öğe
    Weight gain and associated factors in patients using newer antidepressant drugs
    (Elsevier Science Inc, 2015) Uguz, Faruk; Sahingoz, Mine; Gungor, Buket; Aksoy, Fadime; Askin, Rustem
    Objective: The aim of the present study was to examine weight gain and its association with clinical and sociodemographic characteristics in patients using newer antidepressants. Methods: The study had a cross-sectional design. A total of 362 consecutive psychiatric patients taking antidepressant drugs for 6 to 36 months were included in the study. Results: The prevalence rate of weight gain was 55.2%; 40.6% of the patients had a weight gain of 7% or more compared to the baseline. Overall, antidepressant use was significantly related to increased body weight. Specifically, citalopram, escitalopram, sertraline, paroxetine, venlafaxine, duloxetine and mirtazapine, but not fluoxetine, were associated with significant weight gain. Multivariate logistic regression analysis indicated that lower education status, lower body mass index at the onset of antidepressant use and family history of obesity were independent predictors of weight gain >= 7% compared to the baseline. Conclusions: The study results suggest that patients who take newer antidepressants might have significant problems related to body weight. (C) 2015 Elsevier Inc. All rights reserved.